Sugi Predict

Sugi Predict / Compounds / SCHEMBL894796

SCHEMBL894796

SCHEMBL894796

COc1cc(OC)cc(C(N)=O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.64
▸ PARP10 Q53GL7 2/20 0.61
▸ CA1 P00915 1/20 0.61
▸ CA2 P00918 1/20 0.61
▸ PARP2 Q9UGN5 1/20 0.61
▸ PARP4 Q9UKK3 1/20 0.61
▸ PLAU P00749 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.52
▸ PDE4A P27815 1/20 0.49
▸ PDE4B Q07343 1/20 0.49
▸ PDE4C Q08493 1/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.48
▸ F2 P00734 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ APOBEC3A P31941 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ APOBEC3G Q9HC16 1/20 0.48
▸ PRSS1 P07477 1/20 0.48
▸ PRSS2 P07478 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225799 0.95 PARP1 (0.64) PARP1PARP10CA1CA2PARP2
SCHEMBL19828394 0.87 PARP1 (0.56) PARP1PARP10CA1CA2PARP2
SCHEMBL3087859 0.87 PARP1 (0.56) PARP1PARP10CA1CA2PARP2
SCHEMBL14192803 0.87 PARP1 (0.56) PARP1PARP10CA1CA2PARP2
SCHEMBL23360890 0.86 PARP1 (0.55) PARP1PARP10CA1CA2PARP2
SCHEMBL29826907 0.86 PARP1 (0.55) PARP1PARP10CA1CA2PARP2
SCHEMBL7448823 0.86 PARP1 (0.55) PARP1PARP10CA1CA2PARP2
Hydrochloric Acid SCHEMBL28611561 0.86 PARP1 (0.55) PARP1PARP10CA1CA2PARP2
SCHEMBL25432683 0.86 PARP1 (0.55) PARP1PARP10CA1CA2PARP2
SCHEMBL6171991 0.86 PARP1 (0.59) PARP1PARP10CA1CA2PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12575248-B2 Zinc oxide nanomaterial and preparation method thereof and semiconductor device TCL TECHNOLOGY GROUP CORPORATION (CN) 2026-03-10 — — US claimed
CN-119504475-A N-alkylamine compound, preparation method and application 南阳师范学院 2025-02-25 — — CN claimed
EP-4167307-B1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE TCL TECH GROUP CORP (CN) 2025-02-05 — — EP claimed
EP-4167307-A1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE TCL Technology Group Corporation (CN) 2023-04-19 — — EP claimed
WO-2023034413-A2 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 — — WO claimed
CN-113809245-B Zinc oxide nano material, preparation method thereof and semiconductor device TCL科技集团股份有限公司 2022-11-04 — — CN claimed
US-20220336764-A1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREOF AND SEMICONDUCTOR DEVICE U.S. DEPARTMENT OF ENERGY 2022-10-20 — — US claimed
WO-2021253780-A1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE TCL科技集团股份有限公司 2021-12-23 — — WO claimed
CN-113809245-A Zinc oxide nano material, preparation method thereof and semiconductor device TCL科技集团股份有限公司 2021-12-17 — — CN claimed
EP-3762716-A1 A PROTEIN-BINDING PRODUCT, A DEVICE CONTANING SAID PROTEIN-BINDING PRODUCT AND A METHOD FOR EXTRACORPOREAL REDUCTION OF THE LEVEL OF PROTEIN IN BLOOD PLASMA Glycorex Transplantation AB (SE) 2021-01-13 — — EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 — — WO claimed
US-20020128232-A1 Heterocyclic angiogenesis inhibitors STARPHARMA LIMITED (AU) 2002-09-12 — — US claimed
US-6376491-B1 BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS BASILEA PHARMACEUTICA AG (CH) 2002-04-23 — — US claimed
WO-2002030886-A2 HETEROCYCLIC ANGIOGENESIS INHIBITORS MATTHEWS BARRY R (AU) 2002-04-18 — — WO claimed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 — — WO claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 — — EP claimed
EP-1149094-A2 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS Basilea Pharmaceutica AG (CH) 2001-10-31 — — EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 — — WO claimed
WO-2000037464-A2 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS BASILEA PHARMACEUTICA AG (CH) 2000-06-29 — — WO claimed
WO-2000027394-A1 ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE UNIVERSITY COLLEGE LONDON (GB) 2000-05-18 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12575248-B2 Zinc oxide nanomaterial and preparation method thereof and semiconductor device ZRANB2, ZKSCAN2, SLC39A3 PARP1 3305/4885PARP10 2721/4885CA1 1824/4885
US-20020128232-A1 Heterocyclic angiogenesis inhibitors KDR, CBR3, OGFR PARP1 1336/4885PARP10 1782/4885CA1 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.